Skip to main content
Evidence Snapshot

Focal adhesion kinase 1

CHEMBL2695 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T20:05:41Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL2695
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Focal adhesion kinase 1 as ChEMBL target CHEMBL2695, mapped to UniProt Q05397. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Focal adhesion kinase 1
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL2695
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q05397
Focal adhesion kinase 1
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Focal adhesion kinase 1 matters

As of 2026-09-13

Focal adhesion kinase 1 is reviewed as Focal adhesion kinase 1 (UniProt Q05397); Focal adhesion kinase 1 shows late clinical disease relevance led by ovarian cancer. 5 more disease programs remain visible in the same review block.; 2 linked drugs keep this evidence frame grounded.; the current evidence base includes 18 approved drugs, 4188 compounds, and 823 assays, with lead potency reaching pChEMBL 10.2.

Disease context
ovarian cancer

Focal adhesion kinase 1 shows late clinical disease relevance led by ovarian cancer. 5 more disease programs remain visible in the same review block. 2 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include DEFACTINIB, IFEBEMTINIB.

Start review with ovarian cancer because it currently carries late clinical support. Linked drugs include DEFACTINIB, IFEBEMTINIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Late clinical 2 linked drugs
Activity base
Portfolio and assay base

ChEMBL currently tracks 18 approved drugs, 4188 compounds, and 823 assays for this target. The dominant activity type is IC50. CHEMBL4554455 is the current potency anchor at pChEMBL 10.2.

Use CHEMBL4554455 as the tractability anchor when discussing potency (pChEMBL 10.2).

Activity source · ChEMBL 36 via Core Engine
18 approved pChEMBL 10.2
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Focal adhesion kinase 1 matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q05397, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why ovarian cancer is currently treated as late clinical support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

4188
Total Compounds
823
Total Assays
18
Approved Drugs
IC50: 2606.0, KI: 765.0, EC50: 15.0, KD: 500.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL4554455
 10.2 IC50 —
No preferred name
CHEMBL5170906
 10.0 IC50 —
No preferred name
CHEMBL5198068
 10.0 IC50 —
No preferred name
CHEMBL5196177
 9.9 IC50 —
No preferred name
CHEMBL5176233
 9.9 IC50 —

Approved Drugs

Structure Compound First Approval
REPOTRECTINIB
CHEMBL4298138
 2023
FEDRATINIB
CHEMBL1287853
 2019
ENTRECTINIB
CHEMBL1983268
 2019
LORLATINIB
CHEMBL3286830
 2018
BRIGATINIB
CHEMBL3545311
 2017
NINTEDANIB
CHEMBL502835
 2014
CERITINIB
CHEMBL2403108
 2014
BOSUTINIB
CHEMBL288441
 2012
CRIZOTINIB
CHEMBL601719
 2011
SUNITINIB
CHEMBL535
 2006
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T20:05:41Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL2695